Last reviewed · How we verify
Tislelizumab-jsgr
At a glance
| Generic name | Tislelizumab-jsgr |
|---|---|
| Sponsor | Beijing Tongren Hospital |
| Drug class | Programmed Death Receptor-1 Blocking Antibody [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Decreased neutrophil count
- Decreased sodium
- Increased glucose
- Anemia
- Fatigue
- Decreased appetite
- Increased AST
- Decreased potassium
- Increased serum creatinine
- Decreased calcium
- Increased ALT
- Diarrhea
Serious adverse events
- Fatal adverse reactions
- Pneumonia
- Dysphagia
- Diarrhea
- Fatigue
- Esophageal stenosis
- Pneumonitis
Key clinical trials
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy (PHASE1)
- Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tislelizumab-jsgr CI brief — competitive landscape report
- Tislelizumab-jsgr updates RSS · CI watch RSS
- Beijing Tongren Hospital portfolio CI